• Bhagwan Dass, Thomas M Beaver, Michiko Shimada, Kawther F Alquadan, Abhilash Koratala, Girish Singhania, Amardeep Singh, and A Ahsan Ejaz.
• Division of Nephrology, Hypertension and Transplantation, University of Florida, P.O. Box 100224, Gainesville, FL 32610, USA.
• Eur. J. Intern. Med. 2020 Jan 1; 71: 39-44.

ObjectiveThe focus of this review was to elicit the mechanistic logic of the experimental and clinical study designs of natriuretic peptides (NP) in acute kidney injury (AKI) and to understand their respective outcomes.MethodsOnline search of PubMed and manual review of articles. Randomized trials, observational and physiologic studies of NPs and AKI were extracted. Rationale, design and study outcomes were analyzed.ResultsIn experimental models of AKI, infusion of NP prevented post-ischemic fall in renal blood flow (RBF) or improvement in RBF, GFR, diuresis and natriuresis and demonstrated anti-inflammatory properties. NPs were most effective in the early stages of AKI, also in established phase of AKI but their effectiveness were limited to the time of infusion. Hypotension was a major side-effect. Based on these observations, preliminary clinical studies were performed which demonstrated improved urine output, RBF and GFR and reduced need for dialysis. However, randomized, controlled trials failed to demonstrate improvement in dialysis-free survival in different cohorts and study designs. Although NPs reduced the incidence of AKI in the postoperative period in cardiac surgery, it was not associated with improved long-term survival. In contrast to randomized trials, meta-analysis reported favorable results.ConclusionsReasons for the divergence of experimental and clinical outcomes of NPs in AKI are discussed in this review article.Copyright © 2019. Published by Elsevier B.V.

10 keywords...

hide…